Muramyl peptides in the complex treatment of cervical intraepithelial neoplasia associated with human papillomavirus




muramyl peptides, human papilloma virus, cervical intraepithelial neoplasia, colposcopy, Swedish scale


Research objective: the use of an immunomodulator III generation with a wide range of action (muramyl peptide drug Liastenum) to increase the effectiveness of treatment of cervical intraepithelial neoplasia grade I associated with human papilloma virus (HPV) and to reduce the recurrence of cervical pathology.
Materials and methods. The study included 60 women with histologically confirmed cervical intraepithelial neoplasia associated with highly oncogenic HPV. The mean age of patients was 25.92 ± 0.61 years. The first group included 30 women who received traditional treatment, the second group included 30 women who additional received Liastenum 0.002 g intramuscularly 1 time per day, 5 injections per course, after that patients took 1 tablets Liastenum twice a day for 20 days.
Traditional treatment included antibiotic therapy (doxycycline monohydrate), metronidazole, nystatin in standard dosage. Patients with herpes viruses received valaciclovir 500 mg twice/day for 5 days. Evaluation of treatment efficacy was performed at 6 and 12 months with co-testing, fluid cytology, HPV quantification, and colposcopy.
Results. There was a significant decrease in the exposure level of highly oncogenic HPV in the second group compared to the first: after 12 months in the first group HPV was not detected in 2 women (6.67%), and in the second group HPV was no detected in 17 women (56.67%) (p < 0.05). Improvement of the colposcopic picture occurred in 70% of patients in the second group, and in 12 (40.0%) of patients colposcopic conclusion on the Swedish scale was less than 3 points after 12 months of observation. Only 8 (26.67%) women received improvement of the colposcopic picture with a score of 3 points on the Swedish scale in the first group, which was significantly different from the second group (p < 0.05).
Conclusions. Advanced therapy with muramyl peptide Liastenum in the treatment of cervix for 12 months can increase the effectiveness of HPV elimination, improves the colposcopic picture by reducing the area of cervical lesions and normalized cytological picture in 70% of patients with cervical intraepithelial neoplasia grade I.

Author Biography

Y.B. Yakymchuk, I.Y. Horbachevskyi Ternopil National Medical University, Ternopil

PhD, obstetrician-gynecologist, assistant of the Department of Therapy and Family Medicine, Faculty of Postgraduate Education


  1. Drobinskaya, A.N., Khonina, N.A., Pasman, N.M., et al. “Extracorporeal antibiotic therapy and immunotherapy in the treatment of chronic persistent urogenital infections in gynecological patients.” Obstetrics and Gynecology 5 (2006).
  2. Barinsky, I.F., Alimbarova, L.M., Lazarenko, A.A., et al. “Antiviral activity of peptide immunomodulators in experimental infections caused by herpes simplex viruses types 1 and 2.” Problems of Virology 5 (2003).
  3. Drannik, G.N. Clinical immunology and allergology. 3rd ed., add. Кyiv. LLC “Polygraph plus” (2006): 482 p.
  4. Zaykov, S.V. “Liastenum: new original immunomodulator.” Pharmacy Weekly 41.562 (2006).
  5. Zaporozhan, V.N., Tatarchuk, T.F., Dubinina, V.G., et al. “Pretumor pathology of the cervix: the scope of competence of a gynecologist.” Reproductive endocrinology 4.12 (2013): 7–17.
  6. Manukhin, I.B., Minkina, G.N., Vysotsky, M.M., Kharlova, O.G. “Complex treatment of patients with local and widespread cervical condylomatosis.” Questions of gynecology, obstetrics and perinatology 4.6 (2005): 20–4.
  7. Nazarova, N.M., Gusakov, K.I., Sycheva, E.G. “HPV and associated diseases of the cervix uteri in women using hormonal methods of contraception: treatment and diagnostic tactics with abnormal results of cytology.” Medical advice 7 (2019): 34–8. DOI: 10.21518/2079-701X-2019-7-34-38.
  8. Khaitov, R.M. Immunotherapy: A Guide for Physicians. Ed. R.M. Khaitov, R.I. Ataullakhanov, A.E. Shulzhenko. M.: GEOTAR-Media (2018): 768 p.
  9. Pinegin B.V., Andronova T.M., Karsonova M.I. “Muramyldipeptide drugs – new generation immunotropic drugs.” Int J Immunoreabil 6 (1997): 27–33.
  10. Pinegin, B.V., Minkina, G.N., Agikova, L.A., et al. “The use of a new immunomodulator GMDP in the treatment of patients with papillomavirus infection of the cervix.” Immunology 1 (1997): 49–51.
  11. Pynzar, M.A., Agikova, L.A., Minkina, G.N., et al. “Experience in the clinical use of the immunomodulator lycopid in patients with bacterial vaginosis.” Immunology 5 (1998): 63–4.
  12. Savtsova, Z.D., Shpilova, S.I., Tarutinov, V.I., et al. “Immunocorrection for an additional immunomodulator with Lactobacillus delbrueckii in the complex treatment of ailments for breast cancer, stage II–IV.” Oncology 4 (2000): 267–71.
  13. Khaitov, R.M., Ivanova, A.S., Nekrasov, A.V., Patyutko, M.Y. “The results of the use of a new immunomodulator polyoxidonium in patients with postoperative purulent-septic processes.” Actual problems of clinical immunology. Sochi (1994): 109.
  14. Khaitov, R.M., Pinegin, B.V. “Immunomodulators: mechanism of action and clinical use.” Immunology 4 (2003): 196–203.
  15. Khaitov, R.M., Pinegin, B.V., Butakov, A.A., et al. “Immunotherapy of infectious postoperative complications using a new immunostimulant lycopid.” Immunology 2 (1994): 47–50.
  16. Bulletin of the National Cancer Agency of Ukraine No. 22.
  17. Azuma I. “Review: Inducer of cytokines in vivo: overview of field and romurtide experience.” Int J Immunolpharmac 14 (1992): 487–96.
  18. Chrysostomou, A.C., Stylianou, D.C., Constantinidou, A., Kostrikis, L.G. “Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing.” Viruses 10.12 (2018): 729. Published online 2018 Dec 19. DOI: 10.3390/v10120729
  19. Guan, J., Bywaters, S.M., Brendle, S.A., et al. “Cryoelectron microscopy maps of human papillomavirus 16 reveal L2 densities and heparin binding site.” Structure 25 (2017): 253–63. DOI: 10.1016/j.str.2016.12.001
  20. McLucas, B., Vail, E., Chua, K.J., Walt, G. “Cervical intraepithelial neoplasia grade 3 in a patient following Gardasil vaccination.” BMJ Case Rep 12.8 (2019): e230366. DOI: 10.1136/bcr-2019-230366
  21. Van Doorslaer, K., Chen, Z., Bernard, H.U., et al. “ICTV Report Consortium. ICTV Virus Taxonomy Profile: Papillomaviridae.” J Gen Virol 99.8 (2018): 989–90. DOI: 10.1099/jgv.0.001105
  22. Werner, G.H., Jolles, P. “Immunostimulating agents: what next? A review of their present and potential medical applications.” Eur J Immunol 242 (1996): 1–19.
  23. Giannini, S.L., Hubert, P., Doyen, J., et al. “Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix.” Int J Cancer 97 (2002): 654–9.
  24. Denis, M., Chadee, K., Matlashewski, G.J. “Macrophage killing of human papillomavirus type 16-transformed cells.” Virology 170.1 (1989): 342–5.



How to Cite

Yakymchuk, Y. (2021). Muramyl peptides in the complex treatment of cervical intraepithelial neoplasia associated with human papillomavirus. REPRODUCTIVE ENDOCRINOLOGY, (61), 89–94.



Tumors and pretumoral pathology